CSL Seqirus will supply its differentiated influenza vaccine portfolio and, with long-term partner Sinergium Biotech, will localize vaccine filling and distribution. The partnership will...

FOR GLOBAL MEDIA CSL Seqirus will provide adjuvanted cell-based vaccines to support Canada, if an influenza pandemic is declared by the World Health Organization (WHO) Influenza viruses of...

Melbourne, 16 February 2026 CSL Seqirus, part of leading Australian biotechnology company CSL, has today announced that neffy® adrenaline (epinephrine) nasal spray is now available and has been...

Australia’s onshore vaccine manufacturing capabilities took a leap forward today as The Hon Mark Butler MP, Minister for Health, Disability and Ageing,...

Thursday 30 October, Riyadh – CSL Seqirus and Vaccine Industrial Company, have signed a Memorandum of Understanding with the Ministry of Health of Saudi Arabia to enhance the biotechnology...